Please login to the form below

Not currently logged in
Email:
Password:

GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

She will become CEO designate at the HIV-focused firm in January

ViiV Deborah WaterhouseGlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March.

Limet has served as ViiV's CEO since its 2009 formation as a partnership between GSK and Pfizer, with Shionogi subsequently joining the venture in 2012.

He said: “Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and extremely fulfilling personally. I have had the pleasure to work with an exceptional team and am proud of how the business has grown to its current position as a leader in HIV therapy.

“We have delivered scientific innovation, while listening and better understanding the needs of people living with HIV, allowing us to both do good and do well as a business.”

Waterhouse, who is currently senior VP of primary care within GSK's US pharmaceuticals business will take up a CEO designate role at ViiV in January, when she will be replaced by the company's VP of US primary care sales Cheryl MacDiarmid.

23rd December 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics